相关实验视频
Updated: Jan 11, 2026

06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.3K
性直肠炎的临床特征和当前治疗方法
1Jill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Translational gastroenterology and hepatology
|November 11, 2025
概括
性直肠炎 (UP) 是性结肠炎 (UC) 的一个亚型,由于研究有限,它带来了独特的挑战. 需要更多高质量的研究来指导有效的,针对UP患者个性化的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病研究研究
- 临床试验设计 临床试验设计
背景情况:
- 性结肠炎 (UC) 涉及慢性结肠炎症.
- 性直肠炎 (UP),局限于直肠,是一种常见的UC亚型.
- 在有限的特定研究中,UP面临诊断和治疗方面的挑战.
研究的目的:
- 审查性直肠炎 (UP) 研究的现状.
- 识别知识上的差距,指导未来的研究方向.
- 强调需要基于证据的管理策略对UP.
主要方法:
- 文献综述侧重于性直肠炎 (UP) 的诊断和治疗.
- 对现有的随机对照试验 (RCT) 的分析及其对UP的局限性.
- 对UP的诊断标准和当前治疗方法的检查.
主要成果:
- 由于研究设计,定义和结果的变化,UP研究受到阻碍.
- 随机对照试验 (RCT) 通常不包括UP患者,从而限制了证据.
- 像5-ASA和皮质类固醇等一线治疗的有效性已经确立,但先进疗法缺乏UP特异性数据.
结论:
- 对于UP来说,非常需要标准化的指导方针和有针对性的研究.
- 个性化治疗策略和定期监测对于UP管理至关重要.
- 未来的研究应该集中在定义治疗目标和评估UP的新疗法.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Inflammatory Bowel Disease I: Ulcerative Colitis
880
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
880
Peptic Ulcer Disease IV: Management
419
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
419
Inflammatory Bowel Disease V: Surgical Management
430
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
430
Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459
Drugs for Treatment of Constipation-Predominant IBS
686
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
686

